New Zealand markets open in 3 hours 47 minutes

NVS Jul 2023 100.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.8500+0.5400 (+174.19%)
As of 12:17PM EDT. Market open.
Full screen
Previous close0.3100
Expiry date2023-07-21
Day's range0.5500 - 0.8500
Contract rangeN/A
Open interest630
  • GlobeNewswire

    Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer

    Ad hoc announcement pursuant to Art. 53 LR Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1 NATALEE is the first and only positive Phase III study of a CDK4/6 inhibitor demonstrating consistent benefit in a broad population of patients with stage II and III HR+/HER2- early breast cancer (EBC) at risk of recurrence, including those with no nodal involvementApproximately 30-60% of people with HR+/HER2- s

  • Zacks

    Incyte (INCY) Gets CRL for Jakafi Extended-Release Tablets

    The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.

  • Financial Times

    Novartis scraps drug trial in blow to UK life sciences ambitions

    A Swiss pharmaceutical group has scrapped plans to conduct a major drug trial in the UK, damaging government efforts to showcase the country as an attractive destination for investment in life sciences after Brexit. Three years ago Novartis’s decision to collaborate with the NHS on rolling out inclisiran, a twice-yearly injectable drug for lowering cholesterol, was announced to fanfare, after the UK’s slow take-up of innovative medicines compared with peers was criticised. Matt Hancock, health secretary at the time, described it as “a strong vote of confidence in our world-leading life sciences sector”.